Browse Articles
Discover research articles across all indexed journals
Alkane as Hydrogen Source: Pd/Photoredox Dual‐Catalysis Enables Mild Olefin Hydrogenation
ABSTRACT The development of safe and economical catalytic hydrogenation is a persistent challenge. The direct use of abundant alkanes as hydrogen donors under mild conditions is particularly desirable, yet conventional alkane dehydrogenation approaches for this purpose typically require harsh conditions (150°C–200°C) and tolerate a limited range of olefin substrates. Here, we report a cooperative palladium/photoredox catalytic system that enables the hydrogenation of unactivated olefins at room temperature using simple alkanes as the hydrogen source. This dual catalysis merges a photocatalyzed hydrogen atom transfer (HAT) from alkanes with a palladium‐catalyzed hydrogen transfer, achieving efficient olefin hydrogenation. Mechanistic studies support a radical‐mediated pathway and confirm alkanes as the hydrogen source. This operationally simple method exhibits broad substrate scope and functional group tolerance, allowing for the late‐stage modification of complex molecules under mild conditions. This work establishes a general strategy for alkane utilization as convenient and versatile hydrogen donors, offering a mild alternative to traditional hydrogenation methods that generally rely on H 2 gas.
Spatiotemporal differentiation and trade-off/synergy relationships of ecosystem service values in Mountain-Oasis-Desert System of Xinjiang Aksu region
Advancing Lithium–Oxygen Batteries: Pioneering Cathode Catalyst Innovation and Artificial Intelligence‐Driven Design Paradigms
ABSTRACT Lithium‐oxygen batteries (LOBs) are regarded as one of the most promising next‐generation energy storage systems, owing to their exceptionally high theoretical energy density. However, their practical application remains severely hindered by sluggish oxygen reduction and evolution reaction kinetics, insulating discharge products, large voltage polarization, and poor cycling stability. Cathode catalysts play a pivotal role in regulating reaction pathways, accelerating interfacial kinetics, and improving reaction reversibility. This review systematically summarizes the fundamental working principles and key challenges of nonaqueous LOBs, followed by a comprehensive overview of recent advances in cathode catalyst materials, including carbon‐based catalysts, noble metals, transition metal oxides, sulfides, nitrides, carbides, and redox mediators. Particular emphasis is placed on emerging catalyst design strategies, such as single‐atom catalysts, metal–organic frameworks‐derived materials, heterostructure and interfacial engineering, high‐entropy catalysts, and spin‐related oxygen electrocatalysis. In addition, recent progress in high‐throughput computation and artificial intelligence‐driven catalyst design is explored, highlighting the potential for data‐assisted discovery, multiscale structure‐activity relationships, and mechanism‐guided optimization. The review concludes by addressing the critical challenges and outlining future directions for the development of efficient, durable, and practically viable cathode catalysts for nonaqueous LOBs.
Choosing the optimal neoadjuvant backbone for HER2-positive breast cancer: A multicenter real-world comparison of AC-THP and TCHP in Vietnam.
58 Background: In the era of dual HER2 blockade, the optimal neoadjuvant chemotherapy backbone for HER2-positive breast cancer remains controversial, particularly regarding the use of anthracyclines. Multicenter real-world data comparing anthracycline-containing and anthracycline-free regimens in Asian and resource-constrained settings are limited. This study compared the efficacy and safety of AC-THP and TCHP in a multicenter real-world cohort in Vietnam. Methods: We conducted a retrospective multicenter real-world analysis of 140 patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy across multiple oncology centers in Vietnam. Patients received either AC-THP (doxorubicin and cyclophosphamide followed by paclitaxel plus trastuzumab and pertuzumab; n = 52) or TCHP (docetaxel and carboplatin plus trastuzumab and pertuzumab; n = 88). Baseline clinicopathological characteristics, clinical tumor and nodal responses, pathological complete response (pCR), cardiac function, and treatment-related adverse events were analyzed. Results: Patients in the TCHP group were slightly older and more frequently presented with stage II disease. The clinical complete response rate was higher with AC-THP than with TCHP (53.8% vs 40.9%), with a higher clinical nodal response observed in the AC-THP group. pCR rates were comparable between regimens (71.2% with AC-THP vs 70.5% with TCHP). Distinct toxicity profiles were noted. TCHP was associated with higher rates of anemia (52.3% vs 36.5%), thrombocytopenia, and elevated liver enzymes, with grade 3-4 anemia occurring in 8% of patients, whereas no grade 3-4 anemia was observed with AC-THP. In contrast, AC-THP was associated with higher rates of neutropenia and febrile neutropenia. Reduction in left ventricular ejection fraction was infrequent and not clinically different between groups during neoadjuvant treatment. Conclusions: In this multicenter real-world Vietnamese cohort, anthracycline-containing and anthracycline-free neoadjuvant regimens achieved comparable pCR rates despite differing toxicity profiles. These findings support individualized neoadjuvant regimen selection based on patient characteristics and toxicity considerations, particularly in resource-constrained settings. Key efficacy and safety outcomes. Outcome AC-THP (n=52) TCHP (n=88) Median age (years) 45.6 ± 9.8 50.5 ± 10.9 Stage II disease 21 (40.4%) 45 (51.1%) Clinical nodal complete response 40 (76.9%) 56 (63.6%) Clinical (tumor +nodal) complete response 28 (53.8%) 36 (40.9%) Pathological complete response (pCR) 37 (71.2%) 62 (70.5%) Anemia Any grade 19 (36.5%) 46 (52.3%) Grade 3–4 0 (0%) 7 (8.0%) Neutropenia Any grade 27 (51.9%) 40 (45.5%) Grade 3–4 9 (17.3%) 8 (9.0%) Febrile neutropenia 2 (3.8%) 1 (1.1%) Thrombocytopenia 7 (13.5%) 45 (51.1%) LVEF reduction 7 (13.5%) 10 (11.4%)
Development and exploratory evaluation of a prediction model for oral mucositis in patients receiving CapeOX chemotherapy: a multicenter retrospective study
Abstract Oral mucositis (OM) is a clinically significant toxicity in patients receiving CapeOX chemotherapy. However, a prediction model tailored to this population is unavailable. In this multicenter retrospective study, we developed a pragmatic, exploratory and feasibility-based prediction model for OM using routinely collected variables from 1,100 patients with colorectal cancer. Among seven prespecified logistic regression models, the model incorporating CapeOX cumulative exposure (≥ 5 cycles), sex, age, body mass index, smoking history, and platelet count demonstrated the highest discriminative performance in the derivation cohort (ROC–AUC, 0.664). Temporal validation showed limited performance in the validation cohort (ROC–AUC, 0.570), indicating that these routinely available variables captured only part of the inter-individual variability in OM risk. These findings suggest that routinely available clinical variables alone may be insufficient for pretreatment or clinically actionable OM risk prediction, and future models may benefit from integrating oral health-related and treatment-specific factors to enhance predictive accuracy. This study provides exploratory evidence that may inform the future development of more comprehensive and risk-adapted supportive care strategies for patients receiving CapeOX chemotherapy.
High‐Performance Transparent, Deformable, and Recoverable Biomimetic Stevia–PVA Hydrogel Triboelectric Nanogenerator with Machine Learning‐Assisted Motion Recognition
ABSTRACT Rapid breakthroughs in IoT and AI have raised demand for portable, self‐powered, flexible sensor devices. Hydrogels with high conductivity, mechanical tunability, environmental adaptability, and biocompatibility are a clever way to develop flexible sensors for triboelectric nanogenerators. TENG application is limited by the paucity of suitable biomaterials and the need for highly conductive fillers such 2D materials, which trade off transparency, output, and sensing. A unique, very transparent, highly stretchable, high‐output performance biomimetic stevia/PVA hydrogel‐based triboelectric nanogenerator (S‐TENG) is investigated to overcome this issue. Due to its abundant dynamic hydrogen bonding, cost‐effective biomimetic stevia is added to polyvinyl alcohol (PVA) to increase hydrogel cross‐linking and crystalline domains. These structural advancements give the S‐hydrogel 2–5 times the mechanical strength and 3–8 times the electrical output of 2D‐, bio‐, and transparent‐material‐based TENGs, while maintaining transparency. The S‐hydrogel may be recycled and recovered by water‐assisted dissolution and re‐gelation, keeping its voltage output. The improved S‐TENG is a self‐powered sensor for various human motions with great sensitivity and a 13‐ms reaction time. The XGBoost method had the greatest classification accuracy of 95.29% among eleven machine learning models, showing the promise of self‐powered sensors for many applications.
Breast cancer mHealth apps across treatment and survivorship: A systematic review of directly evaluated content and features.
60 Background: Breast cancer survivors report ongoing information and self-management needs from diagnosis through treatment and survivorship. Commercial mHealth apps could support symptom management, decision-making, communication, and survivorship care planning, but it is unclear whether available apps consistently include these features. The purpose of our study was to characterize what breast cancer patients are likely to encounter in the current mHealth app marketplace by synthesizing evidence from published reviews that manually evaluated apps, rather than relying solely on descriptions in the literature. Methods: We conducted a systematic review following PRISMA reporting guidelines. We searched PubMed, Embase, and CINAHL from database inception through September 4, 2024, for studies that directly evaluated commercially available breast cancer mHealth apps and incorporated a patient perspective. Screening and study selection were managed in Covidence. We included studies assessing ≥2 apps, extracted reported app features, and summarized feature prevalence across included studies using descriptive statistics. Results: Informational content was more common than active support functions. Early detection and diagnosis content was variably present (e.g., self-exam 52%; tumor type 28%, stage 25%). Treatment support was limited (treatment management 23%; side effects 20%; medication management 9%; labs 7%; nutrition 6%). Evidence-aligned resources were inconsistent (referenced research 21%; clinical trials 6%). Connection features were scarce, especially patient–clinician communication (4%), general support (6%), and psychosocial support (18%). Survivorship functions were modest (lifestyle modification 29%; care management 23%; survivorship content 21%); end-of-life content was rare (1%). Conclusions: Breast cancer apps evaluated in published manual reviews frequently underdeliver on functions and content most relevant to patients during active treatment and survivorship, particularly communication, survivorship planning, medication support, psychosocial support, and clinical trial information. Multidisciplinary, evidence-aligned app development and evaluation should address these gaps, include explicit survivorship and treatment-transition workflows, and ensure transparent privacy, safety, and health literacy standards to support informed, values-concordant survivorship care decisions.
Study on methane migration flow–solid coupling model under hydraulic borehole conditions and optimization of borehole spacing
The PAN-SUR(IN) score for advanced pancreatic cancer: A comprehensive analysis of methodology, prognostic derivation, and clinical risk stratification.
116 Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by late presentation and aggressive biology. However, outcomes in unresectable or metastatic disease vary widely, ranging from rapid decline to survival exceeding one year. Standard staging systems often fail to account for this granularity. We developed and validated the "PAN-SUR Score," a novel tool based on real-world data to stratify survival risk in advanced PDAC. Methods: A retrospective cohort analysis was conducted on 197 patients with unresectable locally advanced or metastatic PDAC at Surin Hospital, Thailand. Independent predictors of overall survival (OS) were identified using a multivariable flexible parametric survival model. Weighted integer scores were assigned based on beta coefficients. Model discrimination was benchmarked using Harrell’s Concordance Index (C-index) and time-dependent Area Under the Curve (AUC). Results: Five independent prognostic factors were identified: lack of first-line chemotherapy (3 points; aHR 3.71), liver metastasis (1.5 points; aHR 2.00), tumor location (uncinate process [1.5] or head/tail [1] vs. body [0]), BMI <18.0 kg/m² (1 point; aHR 1.64), and initial CA 19-9 ≥1,000 U/mL (1 point; aHR 1.54). The PAN-SUR score demonstrated robust discrimination (C-index 0.718; 6-month AUC 0.86) and stratified patients into three distinct risk groups with significantly divergent median OS: Low-Risk (11.2 months), Intermediate-Risk (5.1 months), and High-Risk (2.3 months). Conclusions: The PAN-SUR score is a practical, objective tool utilizing readily available clinical data. By integrating functional status, tumor biology, and treatment history, it effectively identifies candidates for aggressive therapy versus best supportive care, addressing a critical need for personalized risk assessment in resource-constrained settings. Risk stratification, survival outcomes, and clinical performance of the PAN-SUR score in the derivation cohort. Risk Group Total Score Median OS (Months) 1-Year Survival Probability Low Risk 0 – 2 11.2 40.0% Intermediate Risk 3 – 4 5.1 12.7% High Risk ≥ 5 2.3 3.0%
A Unified Radical C–SuFEx Platform via Catalytic EDA Complex‐Mediated S(VI)─F Bond Activation
ABSTRACT Sulfur(VI) Fluoride Exchange (SuFEx) chemistry has emerged as a powerful tool for forging diverse molecular architectures. While sulfur(VI) fluorides are typically employed as S(VI) + electrophiles in defluorinative reactions with heteroatom nucleophiles, the direct formation of S(VI)─C bonds via C–SuFEx processes remains a significant challenge and is largely underdeveloped. Herein, we report a general and practical radical‐based C‐SuFEx platform that enables the ligation of sulfonyl and sulfonimidoyl fluorides with alkenes and alkynes, providing direct access to alkynyl sulfones, alkenyl sulfones, and alkenyl sulfonimidoyl derivatives. Mechanistic studies support the involvement of a catalytic electron donor–acceptor (EDA) complex formed between triarylamines and sulfur(VI) fluorides, which facilitates mild activation of S(VI)–F bonds to generate key sulfur(VI)‐centered radicals. The synthetic utility of this methodology is further demonstrated through sequential C–SuFEx/cycloaddition transformations, offering a versatile and modular route to structurally diverse and functionally enriched molecular frameworks.
Application of tubeless mini-percutaneous nephrolithotomy under local anesthesia and lateral position in ambulatory surgery: a pilot feasibility study
Early molecular kinetics to predict deep molecular response and inform frontline TKI selection in pediatric chronic myeloid leukemia: A real-world multicenter study.
254 Background: The prognostic utility of adult-derived scoring systems and early molecular response (EMR, defined as BCR :: ABL1 level ≤10% at 3 months) in pediatric chronic myeloid leukemia (CML) requires further validation. This study aimed to evaluate the EUTOS Long-Term Survival (ELTS) score and 3-month molecular response in a real-world pediatric cohort and compare frontline imatinib (IM) versus second-generation tyrosine kinase inhibitors (2G-TKIs). Methods: This multicenter, retrospective study analyzed 248 pediatric CML patients in chronic phase from 13 Chinese hospitals. Molecular responses were assessed per ELN recommendations. The majority (89.9%) received first-line imatinib therapy. The impact of the ELTS risk, 3-month BCR :: ABL1 level, TKI switching, age, baseline bone marrow fibrosis, and spleen size on outcomes was evaluated using Kaplan-Meier and Cox regression analyses. Results: With a median follow-up of 45.3 months, the 5-year overall and progression-free survival rates were 98.9% and 96.2%, respectively. The EMR group had faster rates of achieving major molecular response (MMR: median time 9 vs. 24 months, p≤0.001) and deep molecular response (DMR: median time 18 vs. 50 months, p≤0.001). Cumulative incidences were significantly higher for the EMR group (12-month MMR: 71.4% vs. 21.2%; HR 2.50; p < 0.001; 24-month DMR: 64.7% vs. 27.4%; HR 3.26;p < 0.001). Multivariable analysis confirmed 3-month BCR :: ABL1 > 10% was independent predictors of longer time to MMR and DMR. Furthermore, the EMR attained group also demonstrated superior 5-year event-free survival (74.5% vs. 49.7%; HR 2.89, p = 0.0006) and failure-free survival (73.6% vs. 47.8%; HR 2.92, p = 0.004). Of the patients who remained on their front-line therapy, front-line 2G-TKIs (n = 18) led to a significantly shorter median time to DMR (median time15 vs. 24 months, p = 0.0067) and higher 24-month DMR rate (100% vs. 52.5%, p = 0.00666) compared to IM (n = 168), though 12-month MMR rates were similar. However, baseline ELTS risk stratification (low- vs. intermediate/high-risk) showed no prognostic value for PFS, EFS and FFS. Conclusions: In pediatric CML, early molecular kinetics at 3 months are strong predictors of long-term outcomes. When the treatment goal is rapid and deep molecular response (e.g., aiming for future TFR), frontline 2G-TKIs may offer a significant benefit over IM. This decision must be balanced against their distinct toxicity profiles and cost. The prognostic value of the ELTS score in pediatric CML needs further assessment.
Local Electronic Modulation in Pillararene‐Based Donor–Acceptor Conjugated Polymers for Selective Photocatalytic Oxygen Reduction
ABSTRACT Constructing donor–acceptor (D–A) architectures is a widely adopted strategy for modulating the global band structures of photocatalytic polymers. However, it remains challenging to apply this approach to precisely fine‐tune the local electronic environment of active sites to optimize elementary catalytic steps while preserving the overall conjugated network. In this work, pillararenes with electron‐rich cavities are introduced into D–A conjugated polymers to construct a new material named BTzAP[5], whose reaction mechanism in photocatalytic hydrogen peroxide synthesis is systematically investigated. The electron‐rich cavity of pillararene modulates adjacent imine nitrogen active sites via the extended π‐conjugated system, significantly increasing their electron density, oxygen adsorption, and activation capacities. The tailored structure promotes a rapid stepwise two‐electron ORR pathway of O 2 to H 2 O 2 , with minimal free superoxide accumulation, achieving a production rate of 4086 µmol g −1 h −1 . This work offers a new strategy for achieving synergistic optimization of overall electronic engineering and local design of active sites in D–A type conjugated polymers.
Short-term affective consequences of engaging in brief self-compassion and other-compassion exercises
Abstract Compassion-based interventions are widely used to promote emotional well-being, yet their differential effects on affective arousal level remain poorly understood. The present study examined the immediate affective consequences of brief self- and other-compassion writing exercises, differentiating between positive and negative affect across high- and low-arousal levels. Participants ( N = 230) were randomized to either a self-compassion or an other-compassion condition. General positive affect (PA), high-arousal PA, low-arousal PA, general negative affect (NA), high-arousal NA, and low-arousal NA were assessed before and after the writing task. Mixed ANOVAs with time and conditions as factors were conducted as primary analyses. Results indicated that both conditions were associated with reductions in low-arousal NA, with significantly stronger decreases for self-compassion. Other-compassion additionally showed a significant decrease in high-arousal PA that was not observed in the self-compassion condition. These findings suggest that compassion-based writing exercises produce selective rather than broad immediate affective change, and that practicing compassion for others may carry a short-term affective cost in the form of reduced high-arousal PA. Potentially, this drop in high-arousal PA may function as a barrier to sustained engagement with other-compassion practices, particularly in culture that value high-arousal PA. Pairing other-compassion exercises with activities that boost or restore (high arousal) PA may therefore support more consistent engagement with compassion-based interventions.
Efficacy and safety of first-line PD-1/PD-L1 inhibitor–based therapy in esophageal squamous cell carcinoma: A systematic review and meta-analysis.
113 Background: First-line treatment of esophageal squamous cell carcinoma (ESCC) has evolved with PD-1/PD-L1 inhibitor–based regimens, but survival benefit estimates vary across trials due to differences in checkpoint agents, chemotherapy backbones, and PD-L1 subgroup definitions. Additional phase III trials and updated follow-up data now available prompted this updated meta-analysis to re-estimate efficacy with greater precision. Methods: PubMed, Embase, Scopus, and the Cochrane Library were searched from inception through 2 February 2026 for randomized controlled trials comparing PD-1/PD-L1 inhibitor–based therapy versus chemotherapy in first-line ESCC. Eligible trials reported OS and/or PFS as hazard ratios (HRs) with 95% CIs. Two reviewers independently screened and extracted data. Pooled HRs were calculated using random-effects models; heterogeneity was quantified by I² and τ². Publication bias was assessed by funnel plot. Robustness was evaluated using influence diagnostics (studentized residuals, DFFITS, Cook's distance, covariance ratio), Baujat, radial (Galbraith), and GOSH analyses. Results: Nine randomized phase III trials contributed 13 HR comparisons (N=7,713). PD-1/PD-L1 inhibitor–based therapy improved OS (pooled HR 0.70, 95% CI 0.66–0.74), with all individual comparisons favoring immunotherapy (HR range 0.58–0.77). PFS was also improved (pooled HR 0.64, 95% CI 0.60–0.68); most comparisons were statistically significant (HR range 0.56–0.67), with one estimate crossing unity (HR 0.81, 95% CI 0.64–1.03). Funnel plots showed no clear small-study effect. Influence diagnostics, Baujat/radial plots, and GOSH analyses confirmed the pooled estimates were stable and not driven by any single comparison. Conclusions: PD-1/PD-L1 inhibitor–based first-line therapy significantly improved OS and PFS in ESCC across 13 trial comparisons, with consistent benefit and stable pooled estimates. Further trials are needed to refine patient selection and optimize regimen choice across biomarker subgroups.
3-(4-Hydroxy-3-methoxyphenyl) propionic acid prevents renal fibrosis and inflammation in CKD mice induced by adenine
Reply to: How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia
Real-world genomic profiling of endometrial cancer in south India to identify clinically actionable alterations.
206 Background: Endometrial cancer exhibits substantial molecular heterogeneity with important implications for prognosis and therapeutic selection. While TCGA has defined distinct molecular subgroups, real-world data integrating next-generation sequencing (NGS) to identify actionable alterations and pathway-level dependencies remain limited. This study aimed to characterize the mutational landscape of endometrial cancer using targeted NGS and to evaluate clinically relevant genomic alterations that may inform precision oncology strategies. Methods: A total of 64 endometrial cancer samples were subjected to targeted NGS using a comprehensive oncology panel covering key cancer-related genes. High-quality genomic DNA was extracted, libraries were prepared, and sequencing was performed on an Illumina platform. Bioinformatic analysis included variant calling for single-nucleotide variants and small insertions/deletions, followed by clinical annotation according to ACMG/AMP and ASCO/CAP guidelines. Identified alterations were correlated at gene, pathway, and molecular subgroup levels, including inference of TCGA molecular classes. Results: Somatic mutations were detected across multiple oncogenic pathways. The PI3K–AKT–mTOR pathway was the most frequently altered, with PTEN mutations in 51.6% and PIK3CA mutations in 31.3% of cases. TP53 alterations were identified in 17.2%, consistent with an aggressive molecular subset. Alterations in FGFR2 and KRAS were each observed in 14.1% of cases, highlighting RAS–MAPK pathway involvement. DNA damage response alterations included POLE mutations (6.3%) and MMR gene alterations (MLH1/PMS2, ~6–7%), supporting molecular stratification relevant to immunotherapy. Overall, the cohort was predominantly classified as no specific molecular profile (NSMP), followed by TP53-aberrant, MMR-deficient, and POLE-ultramutated subgroups. Conclusions: Targeted NGS revealed a high prevalence of actionable genomic alterations in endometrial cancer, predominantly driven by PI3K–AKT–mTOR pathway dysregulation. Molecular subclassification identified clinically relevant subsets with potential implications for targeted therapy and immunotherapy selection. These findings support the integration of routine NGS-based profiling into endometrial cancer management to enable precision-guided therapeutic decision-making in real-world clinical settings.
Rapid detection of urinary tract infection by analyzing the dried spots of biological fluids using convolutional neural networks
Efficacy of psychological intervention in children with cancer: A randomized controlled trial.
333 Background: Pediatric cancer patients often experience significant psychological distress due to their diagnosis, treatment side effects, and overall disease burden. Anxiety, depression, acute stress reaction and adjustment disorder are common mental health challenges that negatively impact treatment adherence, well-being, and long-term psychosocial outcomes. Cognitive-behavioral therapy (CBT) has shown positive effects on psychological and health-related outcomes in children with cancer; however, its effectiveness in pediatric cancer patients in Pakistan remains unexplored. Methods: This single-blinded, parallel-group, two-arm randomized controlled trial (RCT) included 80 children (aged 8-14 years) undergoing chemotherapy at the Pediatric Oncology Department of The Children's Hospital, Pakistan Institute of Medical Sciences (PIMS), Islamabad. The intervention group received five weekly, 30-35 minute individual cognitive behavioral therapy (CBT) sessions at the National Autism Center of PIMS, delivered by a consultant psychiatrist trained in CBT, focusing mainly on modifying maladaptive thoughts and promoting behavioral activation, working on coping skills through problem-solving therapy, stress management, anger management, and providing supportive therapy. The control group received usual care. Outcomes were assessed at baseline, post-intervention, and one month after post-intervention using the Revised Child Anxiety and Depression Scale (RCADS) and Pediatric Quality of Life Inventory (PedsQL) 4.0 Core Module. Results: The intervention group showed a significant reduction in anxiety (post-intervention: β = −3.58, 95% CI [−9.04, −4.92], p < 0.001; one-month follow-up: β = −4.26, 95% CI [−9.73, −5.26], p < 0.001) and depression (post-intervention: β = −2.39, 95% CI [−7.64, −1.23], p = 0.001; one-month follow-up: β = −4.12, 95% CI [−7.43, −2.94], p < 0.001), with improvements across generalized anxiety, social anxiety, and major depressive disorder domains. Quality of life (QoL) significantly improved at one-month follow-up (β = 4.07, 95% CI [1.49, 6.18], p = 0.01), particularly in emotional (p = 0.002) and school functioning (p = 0.005). Treatment and medication adherence were higher in the intervention group, with 90 % attending all scheduled chemotherapy sessions compared to 65% in the control group (p = 0.02). Additionally, intervention group experienced reduced sleep disturbances, and improved symptom management, reporting fewer instances of nausea, fatigue, and headaches (p = 0.02). Conclusions: CBT effectively reduces anxiety and depression while enhancing QoL in pediatric cancer patients. These findings support integrating CBT into national standard care protocols for pediatric cancer patients in Pakistan. Future research should explore long-term effects and scalability across diverse healthcare settings.